BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded by Guggenheim to “Strong-Buy” Rating

Guggenheim upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks reports.

Several other research firms have also issued reports on BLSM. JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $28.00 target price on the stock. Leerink Partners initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price target for the company. HC Wainwright assumed coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price objective on the stock. Lifesci Capital assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy” and an average price target of $32.20.

BlossomHill Therapeutics Stock Performance

BlossomHill Therapeutics stock opened at $18.99 on Tuesday. BlossomHill Therapeutics has a 1-year low of $15.25 and a 1-year high of $20.61.

Insider Activity at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Orbimed Advisors Llc bought 625,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This represents a 29.91% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bihua Chen acquired 312,500 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the director owned 3,614,034 shares in the company, valued at approximately $57,824,544. This trade represents a 9.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 1,573,900 shares of company stock worth $25,181,900.

Key Stories Impacting BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners, HC Wainwright, and Guggenheim each upgraded BlossomHill Therapeutics to “strong-buy,” strengthening the analyst consensus around the company. Zacks analyst upgrade coverage
• Positive Sentiment: Lifesci Capital initiated coverage with an “outperform” rating and a $32 price target, implying substantial upside from the current level. Benzinga coverage initiation
• Positive Sentiment: JPMorgan initiated coverage with an “overweight” rating and a $28 price target, adding another major-bank endorsement and signaling confidence in BlossomHill’s growth prospects. Tickerreport JPMorgan coverage
• Positive Sentiment: BlossomHill will present updated Phase 1/2 SOLARA trial data for BH-30643 at the 2026 World Conference on Lung Cancer. The presentation will cover anti-tumor activity in EGFR-mutant non-small-cell lung cancer patients with resistance mutations such as C797S. BH-30643’s FDA Fast Track designation and its potential to address an area without approved oral targeted therapies provide important pipeline catalysts. BlossomHill SOLARA trial data announcement
• Positive Sentiment: A report highlighted insider buying of BlossomHill shares, which may be viewed as a signal of management confidence ahead of upcoming clinical and corporate catalysts. Insider buying report

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.